KD025 is an oral small molecule inhibitor of the Rho-associated coiled-coil kinase (ROCK) signaling pathway and the lead candidate in our ROCK inhibitor platform. In preclinical studies, KD025 down-regulated pro-inflammatory responses and increased T regulatory (Treg) cell function, helping to rebalance the immune response instead of suppressing the entire immune system. In a completed Phase 2 clinical trial in moderate to severe psoriasis, KD025 was well tolerated and demonstrated Psoriasis Area and Severity Index (PASI) score reductions in 85% of patients completing the study.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD billion, while R&D throughout the Group amounted to approximately USD billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http:// .